> ## Content Index
> Fetch the complete content index at: https://www.flavorist.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Abbott Plans to Spin Off Its Nutrition Business: Summary and Analysis
- URL: https://www.flavorist.com/abbott-plans-to-spin-off-its-nutrition-business-summary-and-analysis/
- Published: 2026-10-22T07:45:25.000Z
- Updated: 2026-10-22T07:49:10.000Z
- Author: Editor
- Tags: News

Source: [Food Dive](https://www.fooddive.com/news/abbott-plans-to-spin-out-its-nutrition-business/833620/?ref=flavorist.com), October 21, 2026, with additional detail from Abbott's official announcement.

## Overview

On October 21, 2026, Abbott Laboratories announced plans to separate its global nutrition business into an independent, publicly traded company by the end of 2027.

The new company would have about $8.5 billion in annual sales and would own brands including Similac, Ensure, PediaSure, Pedialyte and Glucerna.

According to Abbott, the separation will let the nutrition business pursue opportunities in functional and health-focused nutrition, while the remaining company concentrates on medical devices, diagnostics and established pharmaceuticals, where it sees stronger growth.

The announcement comes at a time of slower growth and margin pressure in the nutrition segment, as well as ongoing litigation tied to Abbott's infant formula operations. The move separates two businesses with different growth prospects, investment needs and risk profiles.

## 1\. Key terms of the proposed spin-off

| Item                           | Detail                                                                                           |
| ------------------------------ | ------------------------------------------------------------------------------------------------ |
| Nutrition company annual sales | About $8.5 billion                                                                               |
| Remaining Abbott annual sales  | About $42 billion                                                                                |
| Nutrition employees            | About 16,000                                                                                     |
| Manufacturing sites            | 14 worldwide                                                                                     |
| Target completion              | End of 2027                                                                                      |
| Structure                      | Tax-free distribution of shares to existing Abbott shareholders, subject to customary conditions |
| Leadership                     | Daniel Salvadori, currently an Abbott executive, is expected to become CEO                       |
| Remaining Abbott businesses    | Medical devices, diagnostics and established pharmaceuticals                                     |
| Shareholders                   | Expected to hold shares in both companies after the separation                                   |

Sales and employee figures are company projections, not results of a completed transaction.

## 2\. Reasons for the separation

**Focus on higher-growth healthcare businesses.** Abbott's medical device and diagnostics units are tied to growth areas such as cardiovascular care, diabetes technology, diagnostic testing and chronic disease management. Separating nutrition would allow Abbott to direct more investment toward these areas and could improve its overall growth rate and margins.

**Greater independence for nutrition.** The nutrition business serves consumers, patients, healthcare providers and retailers, and its innovation and marketing needs differ from those of a medical device business. As a standalone company, it could allocate capital to product development, brand building, marketing and international expansion without competing for resources with other Abbott divisions.

**A segment that has lagged the rest of the portfolio.** Analysts cited by Food Dive note that nutrition has at times held back Abbott's overall sales growth, and its margins are below the corporate average. Nutrition revenue rose about 5% year over year in the third quarter of 2026, but management believes both businesses will be more attractive to investors if valued separately.

## 3\. Legal and regulatory background

Food Dive highlights the nutrition business's history of regulatory and legal problems:

- **2022 infant formula recall.** Abbott recalled certain powdered infant formulas and temporarily closed its Sturgis, Michigan, plant, which contributed to a nationwide formula shortage.
- **September 2026 settlement.** Abbott announced a $385 million settlement with the U.S. Department of Justice and other parties over claims related to its infant formula operations.
- **August 2026 agreement.** Abbott agreed to pay about $670 million to resolve litigation involving roughly 2,000 claimants over specialty formulas for premature infants and allegations related to necrotizing enterocolitis (NEC), a serious intestinal condition.

Abbott said neither settlement is an admission of liability, and that the government has closed its criminal investigation related to the 2022 formula matter. Other cases remain pending.

Combined, the two settlements total about $1.06 billion.

CEO Robert Ford said that resolving all outstanding litigation is not a condition for completing the spin-off. How future liabilities will be divided between the two companies has not yet been disclosed.

## 4\. Opportunities for the new nutrition company

The standalone company will compete in several major health and nutrition categories:

- **Adult and medical nutrition (Ensure, Glucerna).** Growth areas include healthy aging, high-protein products, chronic disease management and specialized nutrition, supported by consumer interest in muscle maintenance, metabolic health and preventive wellness.
- **Infant and pediatric nutrition (Similac, PediaSure).** These brands hold established positions in formula and children's nutrition, with room to grow internationally. Product safety, regulation, consumer trust and competition remain key considerations.
- **Hydration (Pedialyte).** Pedialyte gives the company a presence in hydration products, a category that extends beyond medical use into everyday wellness and active lifestyles.

Abbott has already been launching products in these areas. In the first half of 2026, it introduced 10 nutrition products, including an Ensure shake with 42 grams of protein, a Similac ready-to-feed formula made with whole milk, and dye-free Pedialyte products.

## 5\. Broader context

**Valuation.** Investors tend to value businesses differently based on growth, margins, risk and capital needs. Medical technology companies typically attract investors focused on innovation-driven growth, while nutrition companies appeal to those seeking established consumer brands with steady demand. Separating the two may make each easier to analyze and value, though a spin-off does not in itself create economic value; both companies will need to deliver consistent operating results.

**Convergence of nutrition and healthcare.** Nutrition companies have traditionally competed on taste, convenience, price and brand. Clinically supported health benefits are becoming a more important point of differentiation. Long-term growth themes include:

- Healthy aging and muscle preservation
- High-protein and specialized nutrition
- Metabolic health and diabetes management
- Medical nutrition for patients with specific dietary needs
- Preventive wellness and personalized nutrition

Abbott's scientific and healthcare background could give the new company an advantage over conventional food and beverage competitors in these areas.

**Industry trend toward simpler portfolios.** The announcement follows similar moves by other healthcare companies. Food Dive points to Medtronic's separation of its diabetes business and Johnson & Johnson's planned separation of its orthopedics business. In each case, the aim is sharper management focus, simpler capital allocation and clearer investment profiles.

## 6\. Financial results and key risks

Abbott announced the spin-off alongside its third-quarter 2026 earnings.

| Metric                             | Reported figure |
| ---------------------------------- | --------------- |
| Q3 2026 total sales                | $13.01 billion  |
| Q3 total sales growth              | 14.5%           |
| Q3 nutrition sales                 | $2.26 billion   |
| Q3 nutrition sales growth          | About 5%        |
| Revised 2026 sales growth outlook  | About 6%        |
| Previous 2026 sales growth outlook | 6.5% to 7.5%    |

The lowered outlook indicates that the spin-off does not address Abbott's near-term operating challenges.

Open questions include whether the nutrition company can improve its margins, how legal liabilities will be allocated, how large the separation costs will be, and how well each company will perform on its own.

## 7\. Assessment

| Potential benefits                                  | Potential challenges                    |
| --------------------------------------------------- | --------------------------------------- |
| More focused strategy for each business             | One-time separation costs               |
| Independent capital allocation                      | Ongoing infant formula litigation       |
| Clearer view of nutrition's value                   | Loss of shared corporate resources      |
| More targeted product development                   | Strong competition and pricing pressure |
| Possible improvement in Abbott's growth and margins | Execution risk during the transition    |

## Conclusion

The spin-off marks Abbott's move away from holding nutrition within a diversified healthcare company. Abbott would concentrate on medical technology and diagnostics, where management expects stronger growth. The nutrition business would have the opportunity to operate as a focused, science-based company serving demand for protein, healthy aging, hydration, metabolic health and specialized nutrition.

The new company will also inherit unresolved litigation, a record of infant formula safety problems and below-average margins. Whether the separation succeeds will depend on whether the two companies deliver better growth, profitability and shareholder returns independently than they did together.

## Sources

- [Food Dive: Abbott plans to spin out its nutrition business](https://www.fooddive.com/news/abbott-plans-to-spin-out-its-nutrition-business/833620/?ref=flavorist.com)
- [Abbott: Official announcement, October 21, 2026](https://abbott.mediaroom.com/2026-10-21-Abbott-announces-its-intention-to-separate-its-global-Nutrition-business-into-an-independent%2C-publicly-traded-company?ref=flavorist.com)

###